Session » Metabolic & Crystal Arthropathies Poster

Date: Saturday, November 7, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 0646

“An Apple Pie a Day Does Not Keep the Doctor Away”. Fictional Depictions of Gout in Contemporary Film and Television

9:00AM-11:00AM: Abstract Number: 0677

A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study

9:00AM-11:00AM: Abstract Number: 0649

A Multicenter, Open-Label, Efficacy and Safety Study of Pegloticase in Patients with Uncontrolled Gout Who Have Undergone Kidney Transplantation: Early Data Report

9:00AM-11:00AM: Abstract Number: 0656

A Sugar Tax Results in Reduced Incident Gout, Quality Adjusted Life Years Lost and Economic Cost from Gout: A Health Economic Analysis

9:00AM-11:00AM: Abstract Number: 0663

Analysis of Common Gout Comorbidities in the UK Biobank Cohort Reveals Sex-Specific Effects and Genetic Differentiation

9:00AM-11:00AM: Abstract Number: 0690

AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate in Patients with Gout in a Phase 2a Study

9:00AM-11:00AM: Abstract Number: 0675

AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers

9:00AM-11:00AM: Abstract Number: 0669

Calcium Pyrophosphate Crystal Deposition in Gouty Tophi

9:00AM-11:00AM: Abstract Number: 0662

Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study

9:00AM-11:00AM: Abstract Number: 0652

Changes in Serum Urate, in the First 6-months of Initiation or Change of Urate-Lowering Therapy, Associate with Immediate Health-Related Quality of Life Outcomes in People with Gout

9:00AM-11:00AM: Abstract Number: 0691

Denosumab Did Not Improve Computerized Tomography Erosion Scores When Added to Intensive Urate-Lowering Therapy in Gout: Results from a Pilot Study

9:00AM-11:00AM: Abstract Number: 0674

Disease Control of Hyperuricemia Newly Detected by Medical Check-up: A Retrospective Cohort Study of Health Insurance Claims Data in Japan

9:00AM-11:00AM: Abstract Number: 0648

Dual Energy CT Has Additional Prognostic Value over Clinical Measures in Gout Including Tophi: Best Evidence Synthesis

9:00AM-11:00AM: Abstract Number: 0647

Dual-energy CT versus Ultrasound, Alone or in Combination, for the Diagnosis of Gout: A Diagnostic Performance Study

9:00AM-11:00AM: Abstract Number: 0679

Epidemiology of Intra-Articular Mineralization on Knee Dual-Energy Computed Tomography: The Multicenter Osteoarthritis Study

9:00AM-11:00AM: Abstract Number: 0661

Genomic Regions Jointly Associated with eGFR and Serum Urate: Implications for Shared Genetic Etiology of Hyperuricemia and Chronic Kidney Disease

9:00AM-11:00AM: Abstract Number: 0657

Gout and Heart Failure in the US

9:00AM-11:00AM: Abstract Number: 0681

Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study

9:00AM-11:00AM: Abstract Number: 0673

Gout Is an Independent Risk Factor for Undergoing an Amputation Procedure

9:00AM-11:00AM: Abstract Number: 0667

Gout Management Beyond Prescription Writing: The Role of the Pharmacist

9:00AM-11:00AM: Abstract Number: 0666

Identification of Intracellular Vacuoles in Synovial Fluid with Calcium Pyrophosphate and Monosodium Urate Crystals

9:00AM-11:00AM: Abstract Number: 0658

Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations

9:00AM-11:00AM: Abstract Number: 0687

Musculoskeletal Manifestations in Patients with CD73 Deficiency

9:00AM-11:00AM: Abstract Number: 0653

Nutrient Content of Gout Flare Trigger Foods

9:00AM-11:00AM: Abstract Number: 0668

Outcomes and Resource Utilization After Total Knee Arthroplasty in Calcium Pyrophosphate Crystal Deposition Disease Patients: Insights from the National Inpatient Sample Database

9:00AM-11:00AM: Abstract Number: 0678

Patient Characteristics and Patterns of Urate-lowering Treatments in Older Patients with Incident Gout

9:00AM-11:00AM: Abstract Number: 0683

Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate

9:00AM-11:00AM: Abstract Number: 0659

Polynesian-Specific Gout-Associated Frameshift Variant in PRPSAP1

9:00AM-11:00AM: Abstract Number: 0672

Prospective Study of the Patterns of Joint Involvement for Sequential Gout Flares

9:00AM-11:00AM: Abstract Number: 0651

Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares

9:00AM-11:00AM: Abstract Number: 0686

Renal Evolution During the First Year of Urate-lowering Therapy According to Sonographic Joint Deposition: Data from the Lille-Alicante Inception Cohort

9:00AM-11:00AM: Abstract Number: 0670

Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study

9:00AM-11:00AM: Abstract Number: 0650

Risk of Vertebral Fractures at Lateral Chest Radiographies in Patients with Gout

9:00AM-11:00AM: Abstract Number: 0682

Role of Inflammatory and Oxidative Stress Pathway Biomarkers in Renal Disease in Gout

9:00AM-11:00AM: Abstract Number: 0660

Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk for Gout – a Comparison Among Canagliflozin, Dapagliflozin and Empagliflozin

9:00AM-11:00AM: Abstract Number: 0671

Structured Cardiovascular Assessment in Gout Incorporating Carotid Ultrasound: Analysis of Subsequent Events in the Follow-Up

9:00AM-11:00AM: Abstract Number: 0676

Surveying Practicing Rheumatologists Regarding Gout Management and Barriers in Gout Care

9:00AM-11:00AM: Abstract Number: 0680

Sustained Treat to Target Uric Acid Lowering Therapy Markedly Lowers Fatty Acids Levels in Gout Patients

9:00AM-11:00AM: Abstract Number: 0689

The Changing Epidemiology of Inpatient Gout and Associated Mortality: A 17-year National Study

9:00AM-11:00AM: Abstract Number: 0688

The Discontinuation of Allopurinol in the Inpatient Setting and the Risk of Gout Flare: A Community-Hospital Experience

9:00AM-11:00AM: Abstract Number: 0654

The Effects of Dietary Macronutrients on Serum Urate: A Secondary Analysis of the OmniHeart Trial

9:00AM-11:00AM: Abstract Number: 0685

The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout

9:00AM-11:00AM: Abstract Number: 0684

The Shrinking Toe: A Sign of Crystal Dissolution During Urate Lowering Treatment of Severe Gouty Arthropathy

9:00AM-11:00AM: Abstract Number: 0665

Trends in Immunomodulation/pegloticase Co-therapy from 2015-2019: A Claims Database Study

9:00AM-11:00AM: Abstract Number: 0664

Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction

9:00AM-11:00AM: Abstract Number: 0655

Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].